Showing results (201-210 of 444) with videos related to

Sort By:
Pageof 45
Respirology (Carlton, Vic.)|July 21, 2022
Treatable traits in the NOVELTY studyAlvar Agustí, Eleni Rapsomaniki, Richard Beasley, et al.
American Journal of Respiratory and Critical Care Medicine|November 12, 2002
Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary diseaseLeonardo M Fabbri, Micaela Romagnoli, Lorenzo Corbetta, et al.
Respiratory Research|October 29, 2025
Modeled reductions in COPD exacerbation rates, mortality, and related medical costs due to increased SITT adoption: PROMETHEUS ItalyPierachille Santus, Bianca Oresta, Davide Finocchiaro, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 2, 2017
Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic TherapiesRohit K Katial, Greg W Bensch, William W Busse, et al.
Respiratory Research|December 20, 2005
Induction and regulation of matrix metalloproteinase-12 in human airway smooth muscle cellsShaoping Xie, Razao Issa, Maria B Sukkar, et al.
Internal and Emergency Medicine|January 19, 2013
Poor adherence to guidelines for long-term oxygen therapy (LTOT) in two Italian university hospitalsAlessia Verduri, Licia Ballerin, Marzia Simoni, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 9, 2002
Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cellsAlberto Papi, Nikolaos G Papadopoulos, Luminita A Stanciu, et al.
Respiratory Research|March 24, 2021
Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trialJinping Zheng, Simonetta Baldi, Li Zhao, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 22, 2017
Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPEROBradley E Chipps, Robert S Zeiger, Allan T Luskin, et al.
The Journal of Allergy and Clinical Immunology|October 9, 2009
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) studyTmirah Haselkorn, James E Fish, Robert S Zeiger, et al.
Pageof 45